NCT03975387: Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known untreated unstable brain metastases – see trial for details; Patients with prior treatment of MDM2 antagonist

Comments are closed.

Up ↑